Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911337 | Lung Cancer | 2012 | 4 Pages |
Abstract
Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-targeted therapy. While first-generation (“reversible”) EGFR tyrosine kinase inhibitors (TKIs) are well established in the treatment of these patients, the remarkably lower efficacy of second-generation (“irreversible”) EGFR-TKIs after failure of reversible EGFR inhibition is far less understood. Here we describe an EGFR-mutated patient treated sequentially with both reversible (erlotinib) and irreversible (afatinib) EGFR-TKIs monitored by sequential [18F]fluorothymidine (FLT-)PET. Our observations confirm the value of molecular imaging for assessment of pharmacodynamics and early prediction of response and relapse in these patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Matthias Scheffler, Carsten Kobe, Thomas Zander, Lucia Nogova, Deniz Kahraman, Roman Thomas, Bernd Neumaier, Markus Dietlein, Jürgen Wolf,